Evidence-Based Treatments for Depression
Antidepressant medications: selective serotonin reuptake inhibitors (SSRIs) including sertraline, escitalopram, fluoxetine, and paroxetine remain first-line pharmacological treatments for MDD. A landmark 2018 Lancet meta-analysis of 522 trials and 116,000 patients by Cipriani et al. conclusively established that all antidepressants tested outperformed placebo (standardized mean difference 0.3-0.5), with effect sizes modest but clinically meaningful — approximately 50-60% of patients respond to initial antidepressant treatment (vs 30-40% placebo response). Escitalopram and sertraline show the best evidence combination of efficacy and tolerability. Response to medication typically requires 4-8 weeks; treatment should continue for 6-12 months after remission to prevent relapse, and indefinitely for those with three or more episodes.
Psychotherapy: cognitive behavioral therapy (CBT) has the strongest evidence base of any psychotherapy for depression, with meta-analyses showing efficacy equivalent to antidepressants for acute depression episodes and superior relapse prevention (particularly MBCT for recurrent depression). CBT addresses the distorted thinking patterns (cognitive distortions including catastrophizing, all-or-nothing thinking, personalization, and mind-reading) and behavioral avoidance patterns that maintain and perpetuate depression. Behavioral activation — a simpler component of CBT focusing on restoring engagement with pleasurable and meaningful activities — is as effective as full CBT for many patients and is more accessible and quickly learnable. Interpersonal therapy (IPT) is equally evidence-supported for depression related to grief, role transitions, and relationship conflict.
Exercise as antidepressant: multiple meta-analyses now confirm that regular aerobic exercise (150+ minutes moderate intensity weekly) produces antidepressant effects equivalent to medication in mild-to-moderate depression — with effects mediated by increased BDNF (brain-derived neurotrophic factor, which promotes neurogenesis), reduced inflammatory cytokines, normalized HPA axis activity, increased monoamine neurotransmitter release, and improved sleep architecture. The Duke University SMILE trials found that exercise was as effective as sertraline for mild-moderate MDD over 16 weeks, with significantly lower relapse rates at 10-month follow-up in the exercise group (9% vs 38%) — a striking finding suggesting that exercise-treated depression is more robustly resolved than medication-treated depression.
Lifestyle interventions with evidence for depression: in addition to exercise, sleep optimization (improving sleep quality and duration reduces depressive symptoms independently, with bidirectional causation), omega-3 supplementation (2g EPA-dominant EPA+DHA daily as adjunct — significant effect in multiple meta-analyses), Mediterranean diet adherence (large prospective SMILES RCT showed significant depression symptom reduction with dietary improvement), social connection (loneliness is a stronger predictor of depression than most clinical risk factors), and nature exposure (green space access is associated with 25-30% lower depression incidence in large urban studies) all have genuine evidence bases that can complement primary treatment.